Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Discovery could help treatments for sickle cell disease

09.08.2016

Research team establishes biomarkers for the inherited blood disorder

An interdisciplinary, international group of researchers has found new biophysical markers that could help improve the understanding of treatments for sickle cell disease, a step toward developing better methods for treating the inherited blood disorder that affects an estimated 80,000 to 100,000 Americans each year.


Researchers have established new biomarkers that could help improve the understanding of sickle cell disease treatments. 1) Researchers separated cells in blood samples from patients with sickle cell disease to isolate cells of different densities. Hydroxyurea, an FDA-approved drug, improved the biophysical markers across all densities. 2) Red blood cells in people with the disease have an abnormal type of hemoglobin that causes the cells to become sickle shaped when they lose oxygen. 3.) The least dense cells were disc-shaped and most like normal red blood cells. 4) When the sickled blood cells return to areas of the body with more oxygen, most of them regain their original shape, while accumulating damages after each sickling cycle. 5) As the cells circulate through the body repeatedly, they gradually become more dense and some of them become irreversibly sickled. Credit: Carnegie Mellon University

Credit: Carnegie Mellon University

"There is a critical need for patient-specific biomarkers that can be used to assess the effectiveness of treatments for sickle cell disease," said Subra Suresh, president of Carnegie Mellon University and co-author of the study. "This study shows how techniques commonly used in engineering and physics can help us to better understand how the red blood cells in people with sickle cell disease react to treatment, which could lead to improved diagnostics and therapies."

The findings from engineers, physicists and clinicians from Carnegie Mellon, the University of Pittsburgh, the Massachusetts Institute of Technology, Florida Atlantic University, Korea University, the Korea Advanced Institute of Science and Technology, and Harvard University will be published this week in the online early edition of the Proceedings of the National Academy of Sciences (PNAS).

People with sickle cell disease have an abnormal form of hemoglobin, a protein found in red blood cells that carry oxygen throughout the body. Normal red blood cells are flexible discs that easily bend and stretch to flow through the body's narrow blood vessels.

In sickle cell disease, the abnormal hemoglobin forms fibers that cause the blood cells to take on a flattened, sickled shape and stiffen when they lose oxygen. This change in shape and rigidity causes the red blood cells to be stuck in the blood vessels and prevents the transport of oxygen to the surrounding tissue. This can cause anemia and extreme pain and impact the health of the body's tissue and organs.

Currently, hydroxyurea is the only FDA-approved drug for sickle cell disease. The drug reduces sickling in red blood cells and is used to treat pain and reduce the need for blood transfusions in some patients, but it does not work in all patients. Researchers have been divided over what mechanisms cause the drug to work. Some believe it works by reactivating fetal hemoglobin, which is better at transporting oxygen than the abnormal hemoglobin that causes sickling. Others believe it works by increasing the volume of red blood cells, reducing the concentration of sickle hemoglobin.

In the current study, the international research team evaluated the biophysical properties -- shape, surface area and volume -- and biomechanical properties -- flexibility and stickiness -- of red blood cells under normal oxygenated conditions using electromagnetic waves to measure small differences in physical properties. The technique, known as common-path interferometric microscopy, allowed researchers to get a three-dimensional view of the cells.

Using blood samples from patients with sickle cell disease, the researchers separated red blood cells into four groups based on their density. Normal, disc-shaped red blood cells were the least dense, while severely sickled cells were the most dense. They then took samples from people receiving hydroxyurea treatment and those not receiving treatment. The red blood cells of those receiving treatment showed an improvement in all of the biophysical and biomechanical properties tested across all density levels. Furthermore, improvement in the physical properties of red blood cells of people treated with hydroxyurea correlated more with an increase in the red blood cell volume than with levels of fetal hemoglobin.

"Our findings shine a light on the mechanism behind hydroxyurea action, which has long been debated in the scientific community," said Ming Dao, principal research scientist in MIT's Department of Materials Science and Engineering and co-author of the study. "It's exciting to see that using the latest optical imaging tools, we can now confirm which one is the dominating mechanism. Understanding the key mechanism of action will allow us to explore novel and improved therapeutic approaches for sickle cell disease."

The researchers hope that these biophysical markers can be combined with biochemical and molecular-level markers to assess things like the severity of a patient's sickle cell disease, determine whether or not a patient will respond to hydroxyurea treatment and monitor the effectiveness of that treatment.

###

Other co-authors of the study are: Poorya Hosseini, Sabia Z. Abidi, Dimitrios P. Papageorgiou, Zahid Yaqoob and Peter T. C. So of MIT; E Du of Florida Atlantic University; Youngwoon Choi of Korea University; YongKeun Park of the Korea Advanced Institute of Science and Technology; John M. Higgins of Harvard; and Gregory J. Kato of the University of Pittsburgh.

The research was funded by the National Institutes of Health (1R01HL121386-01A1, 9P41EB015871-26A1, 5R01NS051320, 5U01HL114476, 4R44EB012415), the National Science Foundation (CBET-0939511), Hamamatsu Corporation, Singapore-MIT Alliance for Research & Technology (SMART) Center, MIT SkolTech Initiative; and Koch Institute for Integrative Cancer Research Bridge Project Initiative.

Media Contact

Jocelyn Duffy
jhduffy@andrew.cmu.edu
412-268-9982

 @CMUScience

http://www.cmu.edu 

Jocelyn Duffy | EurekAlert!

Further reports about: blood cells hemoglobin markers red blood cells volume

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Fraunhofer HHI with latest VR technologies at NAB in Las Vegas

24.04.2017 | Trade Fair News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>